Sara J Adair

10PUBLICATIONS
60CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Microfluidics and nanofluidicsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 20, 2026
KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.

Rachel A Burge, Ozgun Le Roux, Olesja Popow

|Oct 24, 2025
PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer.

Rachel A Burge, Lucas Bialousow, Amanda J Linke

|Aug 12, 2025
The kinase ERK plays a conserved dominant role in the heterogeneity of epithelial-mesenchymal transition in pancreatic cancer cells.

Michelle C Barbeau, Brooke A Brown, Sara J Adair

|Jul 29, 2025
PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer.

Xiaolong Wei, William J Kane, Sara J Adair

|Jun 06, 2025
On-Chip Integration of Impedance Cytometry for Inline Optimization of Dielectrophoretic Separations on Multiple Cellular Biophysical Metrics.

Javad Jarmoshti, Abdullah-Bin Siddique, Aditya Rane

|Mar 14, 2024
Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates.

Arabinda Mandal, Jagathpala Shetty, Christine A Tran

Pageof 2

Frequent Collaborators

8 joint publications

Todd W Bauer

3 joint publications

Nathan S Swami

2 joint publications

Rachel A Burge

2 joint publications

Carlos Honrado